Non Hodgkin Lymphoma Clinical Trial
LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Summary
Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts:
Induction ends on day 19
Consolidation ends on day 38 or 42
Maintenance may include up to 6 cycles
Eligibility Criteria
Inclusion Criteria:
Non-Hodgkin's Lymphoma stages III, IV, IVA with
T cell lymphomas, any primary site irrespective of LDH level
large cell lymphomas, any primary site irrespective of LDH level
B cell lymphomas, any primary site with initial LDH of less than 500
Exclusion Criteria:
B cell lymphomas, any primary site with initial LDH of less than 500 and initial CNS or bone involvement
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10065, United States
How clear is this clinincal trial information?